Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
|
|
- Maude Dennis
- 5 years ago
- Views:
Transcription
1 6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes - France Nantes University Hospital - France Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
2 The Median isn't the message by Stephen Jay Gould The issue is how to be the good candidate for the right part of the curve which can extend out for years and years Ribas A, et al. Clin cancer Res 2012;18: Clinical trials have demonstrated the strenght of IO to increase the number of patients belonging to the right part of the curve.
3 At a glance : immunotherapy into the standards of care EMA (and FDA) approval Immune checkpoint inhibitors Melanoma Non pre-treated NSCLC Pre-treated NSCLC Pre-treated RCC Pre-treated UC Merckel cell carcinoma Pre-treated SCCHN Ipilumumab (3 mg/kg IV q3w x 4) +* Nivolumab (240 mg IV q2w) ** + Pembrolizumab (200 mg IV q3w) + TPS PDL1 50 %** PD-L1 1 %** +** Atezolizumab (1200 mg IV q3w) +** +** Avelumab (10 mg/kg IV q2w) +** Ipi (3 mg/kg) + Nivo (1 mg/kg) + NSCLC : Non Small Cell Lung Cancer ; RCC : Renal Cell Carcinoma ; UC : Urothelial Carcinoma ; SCCHN : squamous cell cancer of the head and neck * Ipilumimab : EMEA approval for unresectable or metastatic melanoma and also FDA approval as adjuvant in stage III ** FDA approval Nivolumab: PD-1 blocking antibody Pembrolizumab: PD-1 blocking antibody Atezolizumab: PD-L1 blocking antibody Avelumab: PD-L1 blocking antibody Ipilimumab : CTLA-4-blocking antibody
4 Adjuvant Ipilimumab in stage III melanoma 951 patients (control arm : placebo) Advantage for 3 efficacy measures : RFS, OS, DM-FS (HR 0.76, 0.72, 0.76) In adjuvant setting, the chosen dose is 10 mg/kg for Ipilimumab Eggermont AMM, et al. N Engl J Med 2016
5 Adjuvant Ipilimumab in stage III melanoma Forest Plot for Overall survival Is there a benefit for stage IIIA? Better benefit for microscopic nodal + Better benefit for ulcerated primary Eggermont AMM, et al. N Engl J Med 2016
6 Immunotherapy in advanced melanoma KEYNOTE CheckMate 037 after progression following Ipilimumab and if BRAF V600 mutation, a BRAF inhibitor CheckMate 066: non pretreated patients with wtbraf melanoma n Phase treatment Primary endpoint Hodi FS 676 III Ipilimumab + gp100 Ipilimumab gp100 Robert C 502 III Ipilimumab + Dacarbazine Dacarbazine + Placebo CheckMate III Nivolumab CT investigator s choice KEYNOTE II Pembrolizumab CT investigator s choice CheckMate III Nivolumab Dacarbazine Hodi FS, et al. N Engl J Med 2010;363(8): Robert C, et al. N Engl J Med 2011;364(26): OS OS OS PFS OS Weber JS, et al. Lancet Oncol 2015;16(4): Ribas A, et al. Lancet Oncol 2015;16(8): Robert C, et al. N Engl J Med 2015;372:
7 Melanoma first choice KEYNOTE-006 (Pembrolizumab) CheckMate 067 (Nivolumab) n 1 year OS* PFS** n PFS Pembrolizumab /2w Pembrolizumab / 3w Ipilimumab % 68.4 % % 5.5 mo. 4.1 mo. 2.8 mo. Nivolumab + Ipilimumab Nivolumab Ipilimumab mo. 6.9 mo. 2.9 mo. *OS : pembro/2w vs docetaxel HR 0.63 ( ) pembro/3w vs docetaxel HR 0.69 ( ) **PFS : pembro /2w vs docetaxel HR 0.58 ( ) pembro /3w vs docetaxel HR 0.58 ( ) PFS : Nivo + Ipi [vs Ipi HR 0.42 ( )]; [vs Nivo HR 0.74( )] Nivo vs Ipi HR 0.57 ( ) Robert C, et al. N Engl J Med 2015; 372(26): Larkin J, et al. N Engl J Med 2015;373(1):23-34.
8 Melanoma : CheckMate 067 and PD-L1 Only 25 % of patients had PD-L1 positive tumors 41 % of patients with PD-L1 negative tumors responded to nivolumab PD-L1 + tumors PD-L1 - tumors n PFS n PFS Nivolumab + Ipilimumab Nivolumab Ipilimumab mo. 14 mo. 3.9 mo. Nivolumab + Ipilimumab Nivolumab Ipilimumab mo. 5.3 mo. 2.8 mo. Robert C, et al. N Engl J Med 2015; 372(26): Larkin J, et al. N Engl J Med 2015;373(1):23-34.
9 Melanoma - Key issues Advance disease Combination or sequential IO Optimal sequencing of targeted therapy and immunotherapy (BRAF V600) Adjuvant setting phase III trial : dabrafenib + trametinib in BRAF mutant stage III melanoma Phase III trial : (1) nivolumab versus ipilimumab ; (2) pembrolizumab versus placebo Atkins MB and Larkin J. J Natl Cancer Inst 2016;108(6):djv414
10 PD-1/PD-L1 inhibitors in NSCLC after platin-based chemo. 5 randomized phase II or III trials CheckMate 017 restricted to squamous histology CheckMate 057 restricted to nonsquamous histology Disease progression after platine based chemotherapy POPLAR and OAK studies allowed 1 2 previous lines KEYNOTE 010 : PD-L1 positive with TPS 1 % n Phase treatment Primary endpoint CheckMate III Nivolumab 3 mg/kg Docetaxel 75 mg/m² CheckMate III Nivolumab 3 mg/kg Docetaxel 75 mg/m² KEYNOTE 010 1,034 II/III Pembrolizumab 2 or 10 mg/kg Docetaxel 75 mg/m² POPLAR 287 II Atezolizumab 1200 mg Docetaxel 75 mg/m² OAK 850 III Atezolizumab 1200 mg Docetaxel 75 mg/m² OS OS OS and PFS OS OS Brahmer J, et al. N Engl J Med Borghaei H, et al. N Engl J Med Fehrenbacher L, et al. Lancet Herbst RS, et al. Lancet Rittmeyer A, et al. Lancet 2017
11 Nivolumab in advanced NSCLC CheckMate 017 (Advanced sqnsclc) CheckMate 057 (Advanced nonsqnsclc) n OS PFS n OS PFS Nivolumab Docetaxel mo. 6.0 mo. HR 0.59 ( ) 3.5 mo. 2.8 mo. HR 0.62 ( ) Nivolumab Docetaxel mo. 9.4 mo. HR 0.73 ( ) 2.3 mo. 4.2 mo. HR 0.92 ( ) Nivolumab : PD-1 inhibitor (IgG4 fully human antibody) Brahmer J, et al. N Engl J Med Borghaei H, et al. N Engl J Med. 2015
12 Nivolumab in advanced NSCLC CheckMate 017 : the OS benefit is independant of PD-L1 expression CheckMate 057 : PD-L1 expression is a predictive biomarker for OS CheckMate 017 (Advanced sqnsclc) CheckMate 057 (Advanced nonsqnsclc) 10.4 vs vs vs vs vs vs 8.0 PD-L1 expression was assessed using Dako clone 28-8 antibody Brahmer J, et al. N Engl J Med Borghaei H, et al. N Engl J Med Paz-Ares L, et al. ASCO Abstract LBA109.
13 Atezolizumab in advanced NSCLC : OAK study Atzolizumab Docetaxel n OS PFS mo. 9.6 mo. HR 0.73 ( ) 2.8 mo. 4.0 mo. HR 0.95 ( ) Rittmeyer A, et al. Lancet 2017
14 Atezolizumab in advanced NSCLC : OAK study On study Prevalence Median OS by PD-L1 expression Median PFS by PD-L1 expression Rittmeyer A, et al. Lancet 2017
15 Pembrolizumab in NSCLC The KEYNOTE-010 trial : Overall population PD-L1 expression on at least 1% of tumour cells (ie, a tumour proportion score 1%). Pembrolizumab 2 Pembrolizumab 10 Docetaxel n OS* PFS** mo mo. 8.5 mo. 3.9 mo. 4.0 mo. 4.0 mo. *OS : pembro 2 vs docetaxel HR 0.71 ( ) pembro 10 vs docetaxel HR 0.61 ( ) **PFS : pembro 2 vs docetaxel HR 0.88 ( ) pembro 10 vs docetaxel HR 0.79 ( ) Pembrolizumab : PD-1 inhibitor (IgG4 humanized antibody) Herbst RS, et al. Lancet 2016
16 PD-1/PD-L1 inhibitors in 1st line metastatic NSCLC 3 randomized trials KEYNOTE-024 : PD-L1 positive with TPS 50 % CheckMate 026 PD-L1 positive 1 % KEYNOTE-021 : restricted for patients with nonsquamous histology n Phase treatment Primary endpoint KEYNOTE III Pembrolizumab 200 mg Platinum doublet chemotherapy CheckMate III Nivolumab 3 mg/kg Investigator s choice (platinum doublet) KEYNOTE II Pemetrexed + carbo + Pembrolizumab 200 mg Pemetrexed + carbo PFS PFS ( 5 % PD-L1+) ORR Reck M, et al. ESMO 2016 and N Engl J Med 2016 Socinscki MA, et al. ESMO 2016 Langer CJ, et al. ESMO 2016 and Lancet Oncol 2016
17 KEYNOTE-024 : PD-L1 positive with TPS 50 % 1934 patients screened 1729 submitted samples 1653 evaluable for PD-L1 500 TPS 50 % (30 %) Pembrolizumab Chemoterapy (platin-based) n PFS OS ORR mdor mo. 6.0 mo. HR 0.50 ( ) NR NR HR 0.60 ( ) 45 % (n=63) 28 % (n=41) NR 6.3 mo. Reck M, et al. ESMO 2016 ; N Engl J Med 2016
18 CheckMate 026 : PD-L1 positive 1 % Nivolumab Chemotherapy n PD-L1 5% PD-L1 25% PD-L1 50% PD-L1 75% % 77.8 % 48.7 % 60.7 % 32.5 % 46.7 % 20.7 % 27.4 % Primary Endpoint (PFS per IRRC in 5% PD-L1+) Overall Survival ( 5% PD-L1+) Nivolumab Chemotherapy (platin-based) n PFS OS mo. 5.9 mo. HR 1.15 ( ) HR 1.02 ( ) Socinscki MA, et al. ESMO 2016
19 KEYNOTE 021 (randomized phase II) Median PFS Median OS Pemetrexed + Carbo + Pembrolizumab Pemetrexed + Carbo n PFS OS ORR mdor mo. 8.9 mo. HR 0.53 ( ) In the chemotherapy alone arm cross over to anti-pd-1/pd-l1 : 51 % NR NR HR 0.90 ( ) 55 % 29 % P= NR NR Langer CJ, et al. ESMO 2016 and Lancet Oncol 2016
20 Conclusion Keynote-024 : validation of pembrolizumab for non pretreated NSCLC with TPS 50 % OAK, CheckMate 017, CheckMate 057 validation of nivolumab and atezolizumab for pre-treated NSCLC KEYNOTE-010 validation of pembrolizumab for pre-treated NSCLC with TPS 1 % Future directions IO combinations, chemo and IO combinations Multiline strategy Other stages of disease: (neo) - adjuvant, locally advanced Other histology (SCLC)
21 Pre-treated advanced renal carcinoma Nivolumab vs everolimus (CheckMate 025) 821 patients pre-treated with one or two regimens of anti-angiogenic therapy the benefit is observed irrespective of PD-L1 expression Motzer RJ, et al. N Engl J Med 2015;373:
22 Atezolizumab : urothelial carcinoma Phase II study with Atezolizumab IMvigor210 OS is associated with PD-L1 expression on immune cells Rosenberg JE, et al. Lancet 2016; 387:
23 Nivolumab : advanced urothelial carcinoma second-line therapy (phase II, CheckMate 275) n = 265 ORR = 19.6 % Sharma P, et al. Lancet Oncol 2017.
24 Pembrolizumab : advanced urothelial carcinoma second-line therapy (phase III, KEYNOTE-045) Pembrolizumab Chemotherapy n PFS OS mo. 3.3 mo. HR 0.98 ( ) 10.3 mo. 7.4 mo. HR 0.73 ( ) Bellmunt J, et al. N Engl J Med 2017.
25 Recurrent or metastatic SCCHN Phase 3 CheckMate-141 (after platinum therapy) SCCHN : Squamous Cell Carcinoma of Head and Neck Ferris RL, et l. N Engl J Med 2016.
26 Immune checkpoint inhibitors : an overview RCC : renal cell carcinoma ; UC : urothelial carcinoma ; SCCHN : squamous cell carcinoma head and neck; NSCLC : non small cell lung cancer ; mcrc : metastatic colorectal cancer Confirmed indications Potential indications Probably not indicated
27 Pembrolizumab in advanced Merckel-Cell carcinoma N=26 ; ORR (n=25) = 56 % [5 CR ; 10 PR] ; PFS-6 month rate : 67 % Indentification of two major factors ultraviolet (UV) light Merkel-cell polyomavirus (MCPyV) : 80 % Nghiem PT, et al. N Engl J Med 2016
28 Avelumab in advanced Merckel-Cell carcinoma N=88 ; ORR = 31.8 % [8 CR ; 20 PR] Kaufman HL et al. Lancet Oncol 2016
29 Solid tumors with microsatellite instability A high level of genetic mutations is described in MSI-H tumors. Expression of neoantigens on tumor cells induces inflamed microenvironment with high expression of immune checkpoints, such as PD-1. Volgestein B, et al. Science 2013
30 MSI-H in solid tumors : a phase II trial 3 cohorts of patients treated with pembrolizumab 10 mg/kg/14 days dmmr mcrc (n=28) pmmr mcrc (n=25) dmmr noncrc* (n=30) ORR 57 % 0 % 71 % Disease control rate 89 % 16 % 71 % mpfs NR 2.3 mo. mos NR 5.98 mo. mcrc : metastatic Colorectal Cancer *ampullary/cholangiocarcinoma; endometrial, small bowel, and gastric cancer. NR : not reached Le DT, et al. N Engl J Med 2015 Le DT, et al. ASCO Abstract 103
31 MSI-H in mcrc : Nivolumab + Ipilimumab Nivolumab Nivolumab + Ipilimumab n ORR Stable Disease mpfs mos % 33.3 % % 51.9 % 5.3 mo. NR 17.1 mo. NR Overman M, et al. ASCO 2016
32 Conclusion (1) Immune checkpoint antibodies are now incorporated in the standard treatments for a number of metastatic disease, eventually depending of certain biomarkers (PD-L1, MSI-H, high mutational load, others) there is a need to evaluate other stages of disease there is a need to evaluate new checkpoint inhibitors (OX40, LAG-3) there is a need to evaluate new combinations, especially for tumors remaining highly resistant to immunotherapy (ex. MEK 1 inhibition promotes T-cell inhibition) Pardoll DM, et al. Nature Reviews Cancer 2012
33 Conclusion (2) hyper- or rapid progressors after immunotherapy Identification of genomic alterations MDM2/MDM4 and EGFR alterations correlated with TTF<2 months TGR (Tumor Growth Rate) prior (REF) and upon (EXP) anti-pd-1/pd-l1 Endometrial stromal carcinoma Kato S, et al. Clin Cancer Res 2017 Champiat S, et al. Clinical Cancer res 2017 Saada-Bouzid E, et al. Ann Oncol 2017
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationImmunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Emily Borders, Pharm.D., M.S., BCOP Oncology Clinical Pharmacist Stephenson Cancer Center Faculty Disclosure Learning Objectives
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationWhat we learned from immunotherapy in the past years
What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationÍndice. Melanoma Cáncer de Pulmón Otros tumores
Índice Melanoma Cáncer de Pulmón Otros tumores Carcinoma de Vejiga Carcinoma de Células Renales Carcinoma de Cabeza y Cuello Carcinomas del tubo digestivo Cáncer de Mama MELANOMA CIRUGÍA CIRUGÍA + INFa
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationCheckpoint inhibitors in the first-line treatment of non-small cell lung cancer
380 Checkpoint inhibitors in the first-line treatment of non-small cell lung cancer L. Decoster, MD 1, K. Vekens, MD 2, S. Mignon, MD 1, D. Schallier, MD, PhD 1, J. De Grève, MD, PhD 1 SUMMARY Antibodies
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationCancer Immunotherapy: an Emerging Paradigm
Cancer Immunotherapy: an Emerging Paradigm Branimir I. Sikic, MD Professor of Medicine Stanford University Nevada Cancer Control Summit Reno, November 6, 217 T-Cell Response: Second Signals to Accelerate
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationThe Present and the Future of Cancer Immunotherapy Biomarkers: Challenges, Opportunities, and Implications for Pathologists
CME The Present and the Future of Cancer Immunotherapy Biomarkers: Challenges, Opportunities, and Implications for Pathologists Course Director and Moderator David L. Rimm, MD, PhD Yale University School
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More information